ALKS
Alkermes Plc
NASDAQ: ALKS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$35.47
-1.34% today
Updated 2026-06-05
Market cap
$7.38B
P/E ratio
49.20
P/S ratio
4.72x
EPS (TTM)
$0.90
Dividend yield
—
52W range
$25 – $46
Volume
2.4M
Alkermes Plc (ALKS) Insider transactions
Net insider activity
Net buying (711,642 shares)
Buy transactions
50
Sell transactions
50
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-12 | WRIGHT, CHRISTOPHER I | Director | Sale | 2,000 | $45.10 | $90200.00 |
| 2026-06-04 | GAFFIN, DAVID JOSEPH | EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $43.05 | $87563.70 |
| 2026-06-01 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Sale | 9,000 | $41.67 | $375043.50 |
| 2026-06-01 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Buy | 5,000 | $19.34 | $96700.00 |
| 2026-06-01 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Sale | 5,000 | — | — |
| 2026-05-29 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Sale | 16,217 | $42.36 | $687007.26 |
| 2026-05-29 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Buy | 12,825 | $19.34 | $248035.50 |
| 2026-05-29 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Buy | 3,392 | $20.03 | $67941.76 |
| 2026-05-29 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Sale | 12,825 | — | — |
| 2026-05-29 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Sale | 3,392 | — | — |
| 2026-05-21 | WRIGHT, CHRISTOPHER I | Director | Sale | 6,142 | — | — |
| 2026-05-21 | WRIGHT, CHRISTOPHER I | Director | Buy | 6,142 | — | — |
| 2026-05-21 | WRIGHT, CHRISTOPHER I | Director | Sale | 1,475 | $36.95 | $54501.25 |
| 2026-05-21 | WILSON, FRANK ANDERS | Director | Sale | 6,142 | — | — |
| 2026-05-21 | WILSON, FRANK ANDERS | Director | Buy | 6,142 | — | — |
| 2026-05-21 | WILSON, FRANK ANDERS | Director | Sale | 1,475 | $36.95 | $54501.25 |
| 2026-05-21 | SNYDERMAN, NANCY LYNN MD | Director | Sale | 6,142 | — | — |
| 2026-05-21 | SNYDERMAN, NANCY LYNN MD | Director | Buy | 6,142 | — | — |
| 2026-05-21 | SNYDERMAN, NANCY LYNN MD | Director | Sale | 1,475 | $36.95 | $54501.25 |
| 2026-05-21 | MCKEON, BRIAN P | Director | Sale | 6,142 | — | — |
| 2026-05-21 | MCKEON, BRIAN P | Director | Buy | 6,142 | — | — |
| 2026-05-21 | MCKEON, BRIAN P | Director | Sale | 1,475 | $36.95 | $54501.25 |
| 2026-05-21 | LURKER, NANCY | Director | Sale | 6,142 | — | — |
| 2026-05-21 | LURKER, NANCY | Director | Buy | 6,142 | — | — |
| 2026-05-21 | LURKER, NANCY | Director | Sale | 1,475 | $36.95 | $54501.25 |
| 2026-05-21 | LAURENCIN, CATO T | Director | Sale | 6,142 | — | — |
| 2026-05-21 | LAURENCIN, CATO T | Director | Buy | 6,142 | — | — |
| 2026-05-21 | LAURENCIN, CATO T | Director | Sale | 1,475 | $36.95 | $54501.25 |
| 2026-05-21 | GAYNOR, RICHARD | Director | Sale | 6,142 | — | — |
| 2026-05-21 | GAYNOR, RICHARD | Director | Buy | 6,142 | — | — |
| 2026-05-21 | GAYNOR, RICHARD | Director | Sale | 1,475 | $36.95 | $54501.25 |
| 2026-05-21 | COOKE, SHANE | Director | Sale | 6,142 | — | — |
| 2026-05-21 | COOKE, SHANE | Director | Buy | 6,142 | — | — |
| 2026-05-21 | COOKE, SHANE | Director | Sale | 3,207 | $36.95 | $118498.65 |
| 2026-05-20 | WRIGHT, CHRISTOPHER I | Director | Buy | 5,409 | — | — |
| 2026-05-20 | WRIGHT, CHRISTOPHER I | Director | Buy | 11,538 | — | — |
| 2026-05-20 | WILSON, FRANK ANDERS | Director | Buy | 5,409 | — | — |
| 2026-05-20 | WILSON, FRANK ANDERS | Director | Buy | 11,538 | — | — |
| 2026-05-20 | SNYDERMAN, NANCY LYNN MD | Director | Buy | 5,409 | — | — |
| 2026-05-20 | SNYDERMAN, NANCY LYNN MD | Director | Buy | 11,538 | — | — |
| 2026-05-20 | MCKEON, BRIAN P | Director | Buy | 5,409 | — | — |
| 2026-05-20 | MCKEON, BRIAN P | Director | Buy | 11,538 | — | — |
| 2026-05-20 | LURKER, NANCY | Director | Buy | 5,409 | — | — |
| 2026-05-20 | LURKER, NANCY | Director | Buy | 11,538 | — | — |
| 2026-05-20 | LAURENCIN, CATO T | Director | Buy | 5,409 | — | — |
| 2026-05-20 | LAURENCIN, CATO T | Director | Buy | 11,538 | — | — |
| 2026-05-20 | GAYNOR, RICHARD | Director | Buy | 5,409 | — | — |
| 2026-05-20 | GAYNOR, RICHARD | Director | Buy | 11,538 | — | — |
| 2026-05-20 | COOKE, SHANE | Director | Buy | 5,409 | — | — |
| 2026-05-20 | COOKE, SHANE | Director | Buy | 11,538 | — | — |
| 2026-05-04 | GAFFIN, DAVID JOSEPH | EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $33.20 | $67528.80 |
| 2026-05-01 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Sale | 9,000 | $33.40 | $300559.50 |
| 2026-05-01 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Buy | 5,000 | $19.34 | $96700.00 |
| 2026-05-01 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Sale | 5,000 | — | — |
| 2026-04-11 | LURKER, NANCY | Director | Sale | 3,751 | — | — |
| 2026-04-11 | LURKER, NANCY | Director | Buy | 3,751 | — | — |
| 2026-04-11 | LURKER, NANCY | Director | Sale | 901 | $33.36 | $30057.36 |
| 2026-04-06 | GAFFIN, DAVID JOSEPH | EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $34.57 | $70315.38 |
| 2026-04-01 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Sale | 9,000 | $35.51 | $319604.40 |
| 2026-04-01 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Buy | 5,000 | $19.34 | $96700.00 |
| 2026-04-01 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Sale | 5,000 | — | — |
| 2026-03-03 | GAFFIN, DAVID JOSEPH | EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $29.76 | $60531.84 |
| 2026-03-02 | REED, JOSHUA | SVP, Chief Financial Officer | Buy | 30,854 | — | — |
| 2026-03-02 | REED, JOSHUA | SVP, Chief Financial Officer | Buy | 66,430 | — | — |
| 2026-03-02 | POPS, RICHARD F | Director, Director and CEO, Alkermes plc | Buy | 88,843 | — | — |
| 2026-03-02 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Buy | 14,176 | — | — |
| 2026-03-02 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Sale | 6,890 | $29.29 | $201808.10 |
| 2026-03-02 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Buy | 15,033 | — | — |
| 2026-03-02 | NICHOLS, CHRISTIAN TODD | SVP, Chief Commercial Officer | Buy | 30,854 | — | — |
| 2026-03-02 | NICHOLS, CHRISTIAN TODD | SVP, Chief Commercial Officer | Sale | 6,000 | $30.00 | $180000.00 |
| 2026-03-02 | NICHOLS, CHRISTIAN TODD | SVP, Chief Commercial Officer | Buy | 66,430 | — | — |
| 2026-03-02 | JACKSON, BLAIR CURTIS | EVP, Chief Operating Officer | Buy | 44,078 | — | — |
| 2026-03-02 | JACKSON, BLAIR CURTIS | EVP, Chief Operating Officer | Buy | 94,900 | — | — |
| 2026-03-02 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Buy | 38,568 | — | — |
| 2026-03-02 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Sale | 9,000 | $29.72 | $267485.40 |
| 2026-03-02 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Buy | 5,000 | $19.34 | $96700.00 |
| 2026-03-02 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Buy | 83,037 | — | — |
| 2026-03-02 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Sale | 5,000 | — | — |
| 2026-03-02 | GAFFIN, DAVID JOSEPH | EVP, CLO, Alkermes, Inc. | Buy | 36,364 | — | — |
| 2026-03-02 | GAFFIN, DAVID JOSEPH | EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $29.29 | $59575.86 |
| 2026-03-02 | GAFFIN, DAVID JOSEPH | EVP, CLO, Alkermes, Inc. | Buy | 78,292 | — | — |
| 2026-02-26 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Sale | 2,747 | — | — |
| 2026-02-26 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Buy | 2,747 | — | — |
| 2026-02-26 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Sale | 808 | $30.73 | $24829.84 |
| 2026-02-26 | NICHOLS, CHRISTIAN TODD | SVP, Chief Commercial Officer | Sale | 5,410 | — | — |
| 2026-02-26 | NICHOLS, CHRISTIAN TODD | SVP, Chief Commercial Officer | Buy | 5,410 | — | — |
| 2026-02-26 | NICHOLS, CHRISTIAN TODD | SVP, Chief Commercial Officer | Sale | 2,403 | $30.73 | $73844.19 |
| 2026-02-26 | JACKSON, BLAIR CURTIS | EVP, Chief Operating Officer | Sale | 8,322 | — | — |
| 2026-02-26 | JACKSON, BLAIR CURTIS | EVP, Chief Operating Officer | Buy | 8,322 | — | — |
| 2026-02-26 | JACKSON, BLAIR CURTIS | EVP, Chief Operating Officer | Sale | 3,695 | $30.73 | $113547.35 |
| 2026-02-26 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Sale | 6,866 | — | — |
| 2026-02-26 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Buy | 6,866 | — | — |
| 2026-02-26 | HOPKINSON, CRAIG C. | EVP R&D, Chief Medical Officer | Sale | 3,049 | $30.73 | $93695.77 |
| 2026-02-26 | GAFFIN, DAVID JOSEPH | EVP, CLO, Alkermes, Inc. | Sale | 6,866 | — | — |
| 2026-02-26 | GAFFIN, DAVID JOSEPH | EVP, CLO, Alkermes, Inc. | Buy | 6,866 | — | — |
| 2026-02-26 | GAFFIN, DAVID JOSEPH | EVP, CLO, Alkermes, Inc. | Sale | 3,049 | $30.73 | $93695.77 |
| 2026-02-23 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Sale | 2,283 | — | — |
| 2026-02-23 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Buy | 2,283 | — | — |
| 2026-02-23 | PARISI, SAMUEL JOSEPH | VP, Finance (Interim PAO) | Sale | 672 | $32.19 | $21631.68 |
| 2026-02-23 | NICHOLS, CHRISTIAN TODD | SVP, Chief Commercial Officer | Sale | 6,407 | — | — |
Frequently asked questions
Are ALKS insiders buying or selling?
Over the transactions on record, ALKS insiders have been net sellers, with about $3.72M in stock sold across 50 sales, against 6 open-market purchases.
Does insider selling at ALKS mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which ALKS insiders are selling the most?
Recent selling is concentrated in a few names. HOPKINSON, CRAIG C. accounts for the largest share on record, with about $1.36M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.